AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 132 min read$UTHR

ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $515.03 ($507.08–$520.96, $4.89M total) across 14 trades on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Aug 13, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The disclosed open-market sale reduces insider share exposure by about $4.89M and may slightly pressure sentiment, but it does not provide new operational, financial, or regulatory information about United Therapeutics.

02

Market read

Traders may treat this as a minor sentiment datapoint rather than a catalyst, given the 10b5-1 pre-arrangement and lack of accompanying company news.

03

What to watch

The article specifies indirect holdings and multiple small trades across a day; traders should avoid over-interpreting directionality without additional insider activity or fundamental catalysts.

Relevance 5/10Novelty 5/10Timing: after-hours/next-session context from a Form 4 filed 2026-08-13 for sales dated 2026-08-12

Background

The article is a SEC Form 4 insider transaction disclosure for United Therapeutics, reported by its CEO and chairperson, Martine Rothblatt, with a stated 10b5-1 plan.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

United Therapeutics CEO and chair Martine Rothblatt sold $4.89M of UTHR shares via an open-market sale under a 10b5-1 plan on 2026-08-12.

Expected impact

Likely limited, short-lived impact unless paired with other news; watch for any follow-on selling signals.

Evidence & confidence

The filing is a primary Form 4 disclosure showing sale size, timing, and 10b5-1 pre-arrangement, which typically reduces interpretive weight versus non-10b5-1 sales.

Market effects

Sector

Insider-sale disclosures can marginally influence sentiment across large-cap biotech, but this filing is company-specific and not sector-wide.

Regional

No clear regional spillover; US-listed issuer filing only.

Global

Limited global relevance because the event is a US insider transaction with no stated international operational change.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • issuer
    United Therapeutics Corp

    Subject of the Form 4 insider transaction disclosure (UTHR).

  • insider
    Martine A. Rothblatt

    Chairperson and CEO who reported the sale of shares via an open-market transaction under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min